MYC Deregulation in Primary Human Cancers.
Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ. · 2017
Read MYC Deregulation in Primary Human Cancers. by Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5485515.txt.
Description
Kalkat and co-authors present a review in Genes on MYC deregulation in human cancers. MYC is a master gene switch for cell growth and division. In healthy cells, its level is kept under tight control. In many cancers, that control breaks down. The authors catalog how often this happens and by what routes.
Gene copying is the most common route, they report. Chromosome swaps, stronger enhancers, and faulty signals also raise MYC levels. The review surveys these modes across many cancer types. Fresh genome studies keep adding new cases. Knowing the exact route of breakdown may reveal drug targets, the authors argue. MYC itself has long resisted direct drugs.
Catalog record
| CREATOR | Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 115 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |